Search results for "Gens"

showing 10 items of 3762 documents

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Analysis of T-Lymphocyte Subsets After Phytohemagglutinin Stimulation in Normal and Type 1 Diabetic Mothers and Their Infants

1992

Our aim was to investigate the immunological status of diabetic pregnancy, which is an overlap of diabetic immunity abnormalities and the immunological modifications normally occurring during pregnancy. METHOD: We studied lymphocyte subpopulations and lymphokine production, after 96 h of phytohemagglutinin (PHA) stimulation, from normal and Type I diabetic pregnant women at delivery time and from the respective cord blood. RESULTS: Peripheral blood mononuclear cells (PBMC) from both normal and Type I diabetic mothers showed an increase in CD8+ and a decrease in CD4+ cells compared to the respective cord blood mononuclear cells (CBMC). Moreover, Type I PBMC showed a lower number of “activate…

Adultmedicine.medical_specialtyCellular immunityCD3ImmunologyPregnancy in DiabeticsLymphocyte ActivationPeripheral blood mononuclear cellInterferon-gammaAntigens CDPregnancyT-Lymphocyte SubsetsInternal medicinemedicineHumansImmunology and AllergyIL-2 receptorPhytohemagglutininsCells CulturedImmunity CellularbiologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryLymphokineObstetrics and GynecologyReceptors Interleukin-2HLA-DR AntigensT lymphocyteFetal BloodFlow CytometryDiabetes Mellitus Type 1EndocrinologyReproductive MedicineCord bloodImmunologybiology.proteinInterleukin-2FemalebusinessCD8Interleukin-1American Journal of Reproductive Immunology
researchProduct

Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losarta…

2009

Abstract The incidence of cardiovascular diseases in premenopausal women is lower than in men or postmenopausal women. This study reports the discovery of a low grade of systemic inflammation, including monocyte adhesion to arterial endothelium, elicited by menopause or estrogen depletion. Chronic treatment with low dose of 17-β-estradiol or inhibition of the renin-angiotensin system reduced this inflammation. Using an in vitro flow chamber system with human arterial and venous endothelial cells, we found that leukocytes from healthy postmenopausal women were more adhesive to the arterial endothelium than those from premenopausal women regardless of the stimulus used on endothelial cells. I…

Adultmedicine.medical_specialtyEndotheliummedicine.drug_classOvariectomyImmunologyInflammationSystemic inflammationLosartanRats Sprague-DawleyInternal medicinemedicineCell AdhesionLeukocytesImmunology and AllergyAnimalsHumansCells CulturedInflammationCell adhesion moleculebusiness.industryEndothelial CellsEstrogensBenzazepinesMiddle Agedmedicine.diseaseRatsMenopausemedicine.anatomical_structureEndocrinologyLosartanEstrogenCase-Control StudiesOvariectomized ratFemaleEndothelium Vascularmedicine.symptomChemokinesMenopausebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion Moleculesmedicine.drugJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Uterine fibroids risk and history of selected medical conditions linked with female hormones

2004

To understand the role of several medical conditions on the risk of uterine fibroids, we analysed the findings of a large case-control study. Cases were 843 women aged 54 or less (median age 43 years, range 21-54) with histologically confirmed uterine fibroids, whose clinical diagnosis dated back no more than 2 years. Indications for surgery were recurrent menorrhagia or ultrasound evidence of fibroids larger than 10 cm in diameter. Controls were 1557 women aged 54 years or less of comparable quinquennia of age (median age 43 years, range 21-54) who had not undergone hysterectomy and were admitted for acute, non-gynecologic, non-hormonal, non-neoplastic conditions to a network of hospitals …

Adultmedicine.medical_specialtyFibroidsUterine fibroidsEpidemiologymedicine.medical_treatmentEpidemiologyMedicineHumansMedical historyRisk factorMedical History TakingGynecologyHysterectomyLeiomyomabusiness.industryCase-control studyEstrogensOdds ratioMiddle Agedmedicine.diseaseEstrogenfemale genital diseases and pregnancy complicationsLeiomyomaItalyCase-Control StudiesEpidemiology; Fibroids; Medical historyMedical historyFemaleCase-Control StudiebusinessHuman
researchProduct

Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.

1991

Hirsutism in women is often explained on the basis of abnormal peripheral androgen metabolism. To determine whether serum markers of ovarian, adrenal, or peripheral androgen production may be helpful determinants in the treatment of hirsutism and to compare the efficacy of treatment with dexamethasone or spironolactone, 20 hyperandrogenic hirsute patients were treated for up to 2 years. Eleven women who were selected on the basis of sensitivity to dexamethasone were treated with a daily dose of 0.37 mg dexamethasone and had androgen levels suppressed into the normal range. Although significant (P less than .05), Ferriman-Gallwey scores decreased only by 20%: 14.2 +/- 0.5 to 11.4 +/- 0.6. Ni…

Adultmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classmedicine.medical_treatmentSpironolactoneAndrogen suppressionAntiandrogenAndrosteroneDexamethasonechemistry.chemical_compoundInternal medicinemedicineHumansTestosteronehirsutismDexamethasoneChemotherapybusiness.industryDehydroepiandrosterone SulfateAndrostenedioneObstetrics and GynecologyAndrogen AntagonistsDihydrotestosteroneGeneral MedicineDehydroepiandrosteroneAndrogenmedicine.diseaseAndrostane-317-diolDrug CombinationsEndocrinologychemistrySpironolactoneAndrogensCorticosteroidFemalebusinessmedicine.drugObstetrics and gynecology
researchProduct

Pancreatitis-associated protein in patients with celiac disease: Serum levels and immunocytochemical localization in small intestine

1997

Since PAP is a stress protein expressed in human pancreas during pancreatitis but also constitutively synthesized in the small intestine, we looked whether its expression would be altered in patients with celiac disease. Serum PAP concentrations were determined consecutively in 54 patients with celiac disease on a free diet (group A), in 47 patients with celiac disease on a gluten-free diet (group B), in 22 patients with other intestinal pathologies but with normal intestinal mucosa (group C), in 14 patients with retarded growth, no gastrointestinal disease and normal intestinal mucosa (group D), and in 17 controls (group E). Serum PAP levels (ng/ml) were significantly higher in group A (12…

Adultmedicine.medical_specialtyPathologyGlutensBiopsyImmunocytochemistryPancreatitis-Associated ProteinsBiologyGastroenterologyCoeliac diseaseJejunumIntestinal mucosaAntigens NeoplasmLectinsInternal medicineIntestine SmallBiomarkers TumormedicineAnimalsHumansLectins C-TypeIntestinal MucosaPancreatitis-Associated ProteinsChildGastroenterologyAcute-phase proteinInfantmedicine.diseaseImmunohistochemistrySmall intestineImmunoglobulin ACeliac DiseaseJejunummedicine.anatomical_structureChild PreschoolImmunoglobulin GPancreatitisFemaleRabbitsAcute-Phase Proteins
researchProduct

Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen–Matched Sibling Transp…

2016

We analyzed the incidence, clinical characteristics, prognostic factors, and outcome of central nervous system (CNS) infections in consecutive patients with receiving umbilical cord blood transplantation (UCBT) (n = 343) or HLA-matched sibling donor stem cell transplantation (MST) (n = 366). Thirty-four CNS infections were documented at a median time of 116 days after transplantation (range, 7 to 1161). The cumulative incidence (CI) risk of developing a CNS infection was .6% at day +30, 2.3% at day +90, and 4.9% at 5 years. The 5-year CI of CNS infection was 8.2% after UCBT and 1.7% after MST (P  .001). The causative micro-organisms of CNS infections were fungi (35%), virus (32%), Toxoplasm…

Adultmedicine.medical_specialtyTime FactorsAdolescentCentral nervous systemHuman leukocyte antigenGastroenterologyYoung Adult03 medical and health sciencesCentral Nervous System Infections0302 clinical medicineHLA AntigensInternal medicinemedicineHumansCumulative incidenceAgedTransplantationbusiness.industryUmbilical Cord Blood TransplantationIncidenceSiblingsIncidence (epidemiology)Hematopoietic Stem Cell TransplantationBacterial InfectionsHematologyMiddle Agedmedicine.diseaseTransplantationmedicine.anatomical_structureMycosesVirus DiseasesHistocompatibility030220 oncology & carcinogenesisImmunologyCord Blood Stem Cell TransplantationStem cellUnrelated DonorsbusinessToxoplasmosisEncephalitis030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

Modulation of oestrogen excretion profiles by adjuvant chemotherapy in pre- and postmenopausal breast cancer.

1985

Modulation of steroid status by conventional chemotherapy was studied in 31 breast cancer patients receiving CMF and in 31 age-matched breast cancer patients without any therapy, taken as controls. This was achieved through the study of oestrogen excretion profiles using previously identified parameters and referring not only to classical but also to the “other”, namely catechol and unusual, oestrogen metabolites. After CMF treatment the premenopausal patients exhibit a modified excretion pattern, mainly concerning a marked and significant reduction of classical oestrogens, as shown by pattern indices. Because there is evidence that oestriol metabolism is not markedly affected by CMF treatm…

Adultmedicine.medical_specialtyTime FactorschlormethineAdjuvant chemotherapymedicine.medical_treatmentBreast NeoplasmsBiochemistryestriolGas Chromatography-Mass SpectrometrySteroidExcretionEndocrinologyBreast cancerInternal medicineestradiolAntineoplastic Combined Chemotherapy ProtocolsmedicineestrogenHumansStage (cooking)CyclophosphamideChromatography High Pressure LiquidAgedbusiness.industryEstrogensMetabolismMiddle Agedmedicine.diseaseestroneEstrogens CatecholEndocrinologyMethotrexateMetabolic rateAdrenal CortexFemaleFluorouracilMenopausebusinessAfter treatmentJournal of steroid biochemistry
researchProduct

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Inn…

2007

To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day −1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follo…

Adultmedicine.medical_specialtyVincristineAntibodies NeoplasmImmunologyKaplan-Meier EstimateCHOPAntibodies Monoclonal HumanizedBiochemistryGastroenterologyChemoimmunotherapyAntigens CDAntigens NeoplasmMulticenter trialInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMulticenter Studies as TopicAlemtuzumabCyclophosphamideSocieties MedicalAgedGlycoproteinsDose-Response Relationship Drugbusiness.industryPralatrexateAntibodies MonoclonalLymphoma T-Cell PeripheralCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryRegimenCD52 AntigenItalyDoxorubicinVincristineAlemtuzumabPrednisonebusinessProgressive diseasemedicine.drug
researchProduct

Variations in central corneal thickness during the menstrual cycle in women.

2007

PURPOSE: We report changes in the central corneal thickness during various phases of the menstrual cycle. METHODS: We recruited 16 healthy women of reproductive age and measured the central corneal thickness at 3 points in their menstrual cycle, beginning on days 1 to 3 and again at ovulation and at the end of the cycle (days 27-32). Ovulation was determined with a test that determines the peak of luteinizing hormone in the urine. RESULTS: We found that the central cornea was thinnest at the beginning of the cycle (mean = 536 microm). Corneal thickness increased at ovulation (mean = 549 microm) and at the end of the cycle (mean = 559 microm). The difference in corneal thickness was statisti…

Adultmedicine.medical_specialtyVisual acuitymedia_common.quotation_subjectVisual AcuityReproductive ageCorneal thickness menstrual cycleCorneaReference ValuesMedicineHumansBody Weights and MeasuresOvulationMenstrual cycleMenstrual Cyclemedia_commonUltrasonographySettore MED/30 - Malattie Apparato Visivobusiness.industryObstetricsFollow up studiesEstrogensSettore MED/40 - Ginecologia E OstetriciaOphthalmologyReference valuesFemalesense organsUltrasonographymedicine.symptombusinessFollow-Up StudiesCornea
researchProduct